“France has always been a Leader in Infectious Disease and Microbiology”

27/06/2016 - 4 minutes

This is what Franck Lescure, a partner at VC firm Auriga Partners, told me when I met him in Paris at his office next to the Champs-Elysées. Their last fund, Auriga IV Bioseeds, focuses on infectious disease and microbiology, with 6 investments so far and 9 by the end of 2016. It was a great way to catch up and understand better what makes Auriga unique (or not).

auriga_partners_logoAuriga has been founded in 1993 and has raised 5 funds so far (over €390M in total) both in life sciences and information technologies. It supported some of the French biotech success stories including Innate-Pharma, Nicox, Erytech and many more. Auriga IV Bioseeds represents €43M, coming from the French government (FNA), the European Investment fund (EIF), several industry players (Pfizer, Sanofi-Pasteur, MSD, Miraca) and other institutions.

To be honest, this didn’t seem so unique to me compared to other specialised early-stage investors in Europe or in France, as for example Sofinnova,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member